SCNX 株価分析 — Scienture Holdings, Inc. (Healthcare >> Pharmaceutical Retailers)
SCNX に関するよくある質問
SCNXのROE(自己資本利益率)は?
Scienture Holdings, Inc.のROEは-0.06%です。
SCNXの配当利回りは?
Scienture Holdings, Inc.の配当利回りは0.00%です。
SCNXの品質スコア(Quality Score)は?
当社のAIはSCNXの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SCNXは今が買い時ですか?
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SCNXはどのセクターに属しますか?
Scienture Holdings, Inc.はHealthcare >> Pharmaceutical Retailersセクターに分類されます(NASDAQ市場)
SCNX AI Analysis Summary
Our AI summary for SCNX: Scienture Holdings, Inc. (NASDAQ), Healthcare >> Pharmaceutical Retailers sector. The stock currently trades at a P/E of 0.00, ROE of -0.06%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.38
Price
-0.00
(-0.29%)
Day Change
|
|
|---|
SCNX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.38 |
| PBV / Sector |
N/A / 0.05
|
| Earning Per Share | -1.03 |
| PE / Sector |
N/A / 0.12
|
| PEG or PE/Growth / Sector |
N/A / 0.00
|
| Average 1M Daily Value |
1.17 M
GREAT
|
| Average 1W Daily Value |
0.09 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
37% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:27 |
| Symbol | SCNX |
| Name | SCIENTURE HOLDINGS, INC. |
| Sector | Healthcare >> Pharmaceutical Retailers |
| Market | NASDAQ |
| Listed Shares | 40.63 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 15.51 / 3.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 20 Austin Boulevard, Commack, NY, United States, 11725
Phone: 631 670 6039
Website: https://scienture.com
Description: Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
ME vs SECTOR Healthcare >> Pharmaceutical Retailers
Click a bubble to view stock details · Bubble size represents market capitalization share
Google